Αποτελέσματα αναζήτησης - "имплантируемый кардиовертер"

1

Academic Journal

Management of Catecholaminergic Polymorphic Ventricular Tachycardia ; Лечение катехоламинергической полиморфной желудочковой тахикардии

Συγγραφείς: Ekaterina K. Kulbachinskaya, Vera V. Bereznitskaya, Е. К. Кульбачинская, В. В. Березницкая

Συνεισφορές: Not specified., Отсутствует.

Πηγή: Current Pediatrics; Том 23, № 2 (2024); 63-70 ; Вопросы современной педиатрии; Том 23, № 2 (2024); 63-70 ; 1682-5535 ; 1682-5527

Θεματικοί όροι: имплантируемый кардиовертер-дефибриллятор, atenolol, propafenone, primary channelopathy, sudden cardiac death, left side sympathectomy, implantable cardioverter defibrillator, атенолол, пропафенон, первичная каналопатия, внезапная сердечная смерть, левосторонняя симпатэктомия

Περιγραφή αρχείου: application/pdf

Relation: https://vsp.spr-journal.ru/jour/article/view/3449/1364; Pflaumer A, Davis AM. An Update on the Diagnosis and Management of Catecholaminergic Polymorphic Ventricular Tachycardia. Heart Lung Circ. 2019;28(3):366–369. doi: https://doi.org/10.1016/j.hlc.2018.10.016; Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43(40):3997–4126. doi: https://doi.org/10.1093/eurheartj/ehac262; Kurtzwald-Josefson E, Hochhauser E, Katz G, et al. Exercise training improves cardiac function and attenuates arrhythmia in CPVT mice. J Appl Physiol (1985). 2012;113(11):1677–1683. doi: https://doi.org/10.1152/japplphysiol.00818.2012; Ostby SA, Bos JM, Owen HJ, et al. Competitive Sports Participation in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia: A Single Center’s Early Experience. JACC Clin Electrophysiol. 2016;2(3):253–262. doi: https://doi.org/10.1016/j.jacep.2016.01.020; Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793–867l. doi: https://doi.org/10.1093/eurheartj/ehv316; Ackerman MJ, Priori SG, Dubin AM, et al. Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: Are all beta-blockers equivalent? Heart Rhythm. 2017;14(1):e41–e44. doi: https://doi.org/10.1016/j.hrthm.2016.09.012; Leren IS, Saberniak J, Majid E, et al. Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with β1-selective β-blockers in patients with catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2016;13(2):432–440. doi: https://doi.org/10.1016/j.hrthm.2015.09.029; Peltenburg PJ, Kallas D, Bos JM, et al. An International Multicenter Cohort Study on β-Blockers for the Treatment of Symptomatic Children With Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation. 2022;145(5):333–344. doi: https://doi.org/10.1161/CIRCULATIONAHA.123.064786; Hayashi M, Denjoy I, Extramiana F, et al. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation. 2009;119(18):2426–2434. doi: https://doi.org/10.1161/CIRCULATIONAHA.108.829267; Roston TM, Vinocur JM, Maginot KR, et al. Catecholaminergic Polymorphic Ventricular Tachycardia in Children: Analysis of Therapeutic Strategies and Outcomes from an International Multicenter Registry. Circ Arrhythm Electrophysiol. 2015;8(3):633–642. doi: https://doi.org/10.1161/CIRCEP.114.002217; Sumitomo N, Harada K, Nagashima M, et al. Catecholaminergic polymorphic ventricular tachycardia: Electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. Heart. 2003;89(1):66–70. doi: https://doi.org/10.1136/heart.89.1.66; Березницкая В.В., Кульбачинская Е.К., Школьникова М.А. Особенности клинических проявлений и эффективность антиаритмической терапии у больных с катехоламинергической полиморфной желудочковой тахикардией // Вестник аритмологии. — 2021.—Т.28.—№4.—С.62–69.—doi:https://doi.org/10.35336/VA-2021-4-62-69; Кульбачинская Е.К., Березницкая В.В. CASQ2: клинико-генетические особенности катехоламинергической полиморфной желудочковой тахикардии в трех семьях // Альманах клинической медицины. — 2023. — Т. 51. — № 3. — С. 192–199. — doi: https://doi.org/10.18786/2072-0505-2023-51-022; Mazzanti A, Kukavica D, Trancuccio A, et al. Outcomes of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia Treated With β-Blockers. JAMA Cardiol. 2022;7(5):504–512. doi: https://doi.org/10.1001/jamacardio.2022.0219; Veith M, El-Battrawy I, Roterberg G, et al. Long-Term Follow-Up of Patients with Catecholaminergic Polymorphic Ventricular Arrhythmia. J Clin Med. 2020;9(4):903. doi: https://doi.org/10.3390/jcm9040903; Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2002;106(1):69–74. doi: https://doi.org/10.1161/01.cir.0000020013.73106.d8; Marai I, Khoury A, Suleiman M, et al. Importance of ventricular tachycardia storms not terminated by implantable cardioverter defibrillators shocks in patients with CASQ2 associated catecholaminergic polymorphic ventricular tachycardia. Am J Cardiol. 2012;110(1):72–76. doi: https://doi.org/110.1016/j.amjcard.2012.02.049; Kawata H, Ohno S, Aiba T, et al. Catecholaminergic polymorphic ventricular tachycardia (CPVT) associated with ryanodine receptor (RyR2) gene mutations: Long-term prognosis after initiation of medical treatment. Circ J. 2016;80(9):1907–1915. doi: https://doi.org/10.1253/circj.CJ-16-0250; Li Y, Peng X, Lin R, et al. The Antiarrhythmic Mechanisms of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia. Front Physiol. 2022;13:850117. doi: https://doi.org/10.3389/fphys.2022.850117; Salvage SC, Huang CL, Fraser JA, Dulhunty AF. How does flecainide impact RyR2 channel function? J Gen Physiol. 2022;154(9): e202213089. doi: https://doi.org/10.1085/jgp.202213089; Bannister ML, MacLeod KT, George CH. Moving in the right direction: elucidating the mechanisms of interaction between flecainide and the cardiac ryanodine receptor. Br J Pharmacol. 2022;179(11):2558–2563. doi: https://doi.org/10.1111/bph.15718; Kryshtal DO, Blackwell DJ, Egly CL, et al. RYR2 Channel Inhibition Is the Principal Mechanism of Flecainide Action in CPVT. Circ Res. 2021;128(3):321–331. doi: https://doi.org/10.1161/CIRCRESAHA.120.316819; Kannankeril PJ, Moore JP, Cerrone M, et al. Efficacy of flecainide in the treatment of catecholaminergic polymorphic ventricular tachycardia a randomized clinical trial. JAMA Cardiology. 2017;2(7):759–766. doi: https://doi.org/10.1001/jamacardio.2017.1320; Khoury A, Marai I, Suleiman M, et al. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2013;10(11):1671–1675. doi: https://doi.org/10.1016/j.hrthm.2013.08.011; Watanabe H, Van Der Werf C, Roses-Noguer F, et al. Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2013;10(4):542–547. doi: https://doi.org/10.1016/j.hrthm.2012.12.035; Jacquemart C, Ould Abderrahmane F, Massin MM. Effects of flecainide therapy on inappropriate shocks and arrhythmias in catecholaminergic polymorphic ventricular tachycardia. J Electrocardiol. 2012;45(6):736–738. doi: https://doi.org/10.1016/j.jelectrocard.2012.05.002; Pott C, Dechering DG, Reinke F, et al. Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: A case report and review of the current literature. Europace. 2011;13(6):897–901. doi: https://doi.org/10.1093/europace/euq517; Padfield GJ, AlAhmari L, Lieve KV, et al. Flecainide monotherapy is an option for selected patients with catecholaminergic polymorphic ventricular tachycardia intolerant of beta-blockade. Heart Rhythm. 2016;13(2):609–613. doi: https://doi.org/10.1016/j.hrthm.2015.09.027; Savio-Galimberti E, Knollmann BC. Channel activity of cardiac ryanodine receptors (RyR2) determines potency and efficacy of flecainide and R-propafenone against arrhythmogenic calcium waves in ventricular cardiomyocytes. PLoS One. 2015;10(6):e0131179. doi: https://doi.org/10.1371/journal.pone.0131179; Marx A, Lange B, Nalenz C, et al. A 35-year effective treatment of catecholaminergic polymorphic ventricular tachycardia with propafenone. HeartRhythm Case Reports. 2019;5(2):74–77. doi: https://doi.org/10.1016/j.hrcr.2018.04.003; Li S, Lv T, Yang J, et al. A gain of function ryanodine receptor 2 mutation (R1760W-RyR2) in catecholaminergic polymorphic ventricular tachycardia. Clin Exp Pharmacol Physiol. 2023;50(1):39–49. doi: https://doi.org/10.1111/1440-1681.13722; Vaksmann G, Klug D. Efficacy of ivabradine to control ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia. Pacing Clin Electrophysiol. 2018;41(10):1378–1380. doi: https://doi.org/10.1111/pace.13446; Kohli U, Aziz Z, Beaser AD, Nayak HM. A large deletion in RYR2 exon 3 is associated with nadolol and flecainide refractory catecholaminergic polymorphic ventricular tachycardia. Pacing Clin Electrophysiol. 2019;42(8):1146–1154. doi: https://doi.org/10.1111/pace.13668; Roston TM, Hart A, Krahn AD, Sanatani S. The challenge of implantable cardioverter-defibrillator programming and shock interpretation in treatment-refractory catecholaminergic polymorphic ventricular tachycardia. J Cardiovasc Med (Hagerstown). 2019;20(8):569–571. doi: https://doi.org/10.2459/JCM.0000000000000814; Miyake CY, Webster G, Czosek RJ, et al. Efficacy of implantable cardioverter defibrillators in young patients with catecholaminergic polymorphic ventricular tachycardia: Success depends on substrate. Circ Arrhythm Electrophysiol. 2013;6(3):579–587. doi: https://doi.org/10.1161/CIRCEP.113.000170; Eckert H, El-Battrawy I, Veith M, et al. Pooled Analysis of Complications with Transvenous ICD Compared to Subcutaneous ICD in Patients with Catecholaminergic Polymorphic Ventricular Arrhythmia. J Pers Med. 2022;12(4):536. doi: https://doi.org/10.3390/jpm12040536.; Pizzale S, Gollob MH, Gow R, Birnie DH. Sudden death in a young man with catecholaminergic polymorphic ventricular tachycardia and paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol. 2008;19(12):1319–1321. doi: https://doi.org/10.1111/j.1540-8167.2008.01211.x; Itoh H, Murayama T, Kurebayashi N, et al. Sudden death after inappropriate shocks of implantable cardioverter defibrillator in a catecholaminergic polymorphic ventricular tachycardia case with a novel RyR2 mutation. J Electrocardiol. 2021;69:111-118. doi: https://doi.org/10.1016/j.jelectrocard.2021.09.015; Richardson E, Spinks C, Davis A, et al. Psychosocial Implications of Living with Catecholaminergic Polymorphic Ventricular Tachycardia in Adulthood. J Genet Couns. 2018;27(3):549-557. doi: https://doi.org/10.1007/s10897-017-0152-1; Roses-Noguer F, Jarman JWE, Clague JR, Till J. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2014;11(1):58-66. doi: https://doi.org/10.1016/j.hrthm.2013.10.027; Roston TM, Jones K, Hawkins NM, et al. Implantable cardioverter-defibrillator use in catecholaminergic polymorphic ventricular tachycardia: A systematic review. Heart Rhythm. 2018;15(12):1791-1799. doi: https://doi.org/10.1016/j.hrthm.2018.06.046; Van Der Werf C, Lieve KV, Bos JM, et al. Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest. Eur Heart J. 2019;40(35):2953-2961. doi: https://doi.org/10.1093/eurheartj/ehz309; Mohamed U, Gollob MH, Gow RM, Krahn AD. Sudden cardiac death despite an implantable cardioverter-defibrillator in a young female with catecholaminergic ventricular tachycardia. Heart Rhythm. 2006;3(12):1486-1489.; Sy RW, Gollob MH, Klein GJ, et al. Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2011;8(6):864-871. doi: https://doi.org/10.1016/j.hrthm.2011.01.048; De Ferrari GM, Dusi V, Spazzolini C, et al. Clinical Management of Catecholaminergic Polymorphic Ventricular Tachycardia: The Role of Left Cardiac Sympathetic Denervation. Circulation. 2015;131(25):2185-2193. doi: https://doi.org/10.1161/CIRCULATIONAHA.115.015731; Schwartz PJ, Snebold NG, Brown AM. Effects of unilateral cardiac sympathetic denervation on the ventricular fibrillation threshold. Am J Cardiol. 1976;37(7):1034-1040. doi: https://doi.org/10.1016/0002-9149(76)90420-3; Yagishita D, Chui RW, Yamakawa K, et al. Sympathetic nerve stimulation, not circulating norepinephrine, modulates T-peak to T-end interval by increasing global dispersion of repolarization. Circ Arrhythm Electrophysiol. 2015;8(1):174-185. doi: https://doi.org/10.1161/CIRCEP.114.002195; Jonesco T. Traitement chirurgical de l'angine de poitrine par la resection dusympathique cervico-thoracique. Presse Med. 1921;20:30.; Moss AJ, McDonald J. Unilateral cervicothoracic sympathetic ganglionectomy for the treatment of long QT interval syndrome. N Engl J Med. 1971;285(16):903-904. doi: https://doi.org/10.1056/NEJM197110142851607; Schwartz PJ, Periti M, Malliani A. The long Q-T syndrome. Am Heart J. 1975;89(3):378-390. doi: https://doi.org/10.1016/0002-8703(75)90089-7; Schwartz PJ, Malliani A. Electrical alternation of the T-wave: clinical and experimental evidence of its relationship with the sympathetic nervous system and with the long Q-T syndrome. Am Heart J. 1975;89(1): 45-50. doi: https://doi.org/10.1016/0002-8703(75)90008-3; Wilde AAM, Bhuiyan ZA, Crotti L, et al. Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. N Engl J Med. 2008;358(19):2024-2029. doi: https://doi.org/10.1056/NEJMoa0708006; Atallah J, Fynn-Thompson F, Cecchin F, et al. Video-Assisted Thoracoscopic Cardiac Denervation: A Potential Novel Therapeutic Option for Children With Intractable Ventricular Arrhythmias. Ann Thorac Surg. 2008;86(5):1620-1625. doi: https://doi.org/10.1016/j.athoracsur.2008.07.006; Schwartz PJ, Ackerman MJ. Cardiac sympathetic denervation in the prevention of genetically mediated life-threatening ventricular arrhythmias. Eur Heart J. 2022;43(22):2096-2102. doi: https://doi.org/10.1093/eurheartj/ehac134; Cho Y. Left cardiac sympathetic denervation: An important treatment option for patients with hereditary ventricular arrhythmias. J Arrhythm. 2016;32(5):340-343. doi: https://doi.org/10.1016/j.joa.2015.08.002; Schwartz PJ, Locati EH, Moss AJ, et al. Left cardiac sympathetic denervation in the therapy of congenital long QT syndrome. A worldwide report. Circulation. 1991;84(2):503-511. doi: https://doi.org/10.1161/01.cir.84.2.503; Li C, Hu D, Shang L, et al. Surgical left cardiac sympathetic denervation for long QT syndrome: effects on QT interval and heart rate. Heart Vessels. 2005;20(4):137-141. doi: https://doi.org/10.1007/s00380-005-0820-1; Waddell-Smith KE, Ertresvaag KN, Li J, et al. Physical and Psychological Consequences of Left Cardiac Sympathetic Denervation in Long-QT Syndrome and Catecholaminergic Polymorphic Ventricular Tachycardia. Circ Arrhythm Electrophysiol. 2015;8(5): 1151-1158. doi: https://doi.org/10.1161/CIRCEP.115.003159; Dusi V, De Ferrari GM, Pugliese L, Schwartz PJ. Cardiac Sympathetic Denervation in Channelopathies. Front Cardiovasc Med. 2019;6:27. doi: https://doi.org/10.3389/fcvm.2019.00027; Perez PR, Hylind RJ, Roston TM, et al. Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia. Heart Lung Circ. 2023;32(7):790-797. doi: https://doi.org/10.1016/j.hlc.2023.01.018

Διαθεσιμότητα: https://vsp.spr-journal.ru/jour/article/view/3449
https://doi.org/10.15690/vsp.v23i2.2740

View record from BASE

2

Academic Journal

Analysis of electrotherapy in patients with implantable cardioverter-defibrillator for primary prevention of sudden cardiac death according to remote monitoring data ; Анализ электротерапии у пациентов с имплантированным кардиовертером-дефибриллятором для первичной профилактики внезапной сердечной смерти по данным удаленного мониторинга

Συγγραφείς: V. K. Lebedeva, O. E. Levinova, В. К. Лебедева, О. Э. Левинова

Πηγή: Siberian Journal of Clinical and Experimental Medicine; Том 38, № 4 (2023); 106-115 ; Сибирский журнал клинической и экспериментальной медицины; Том 38, № 4 (2023); 106-115 ; 2713-265X ; 2713-2927

Θεματικοί όροι: необоснованный шок, implantable cardioverter-defibrillator, electrotherapy, inappropriate shock, имплантируемый кардиовертер-дефибриллятор, электротерапия

Περιγραφή αρχείου: application/pdf

Relation: https://www.sibjcem.ru/jour/article/view/2059/895; Barisone M., Hayter M., Ghirotto L., Catania G., Zanini M., Dal Molin A. et al. The experience of patients with an implantable cardioverter-defibrillator: a systematic review and meta-synthesis of qualitative studies. Eur. J. Cardiovasc. Nurs. 2022;21(7):677–686. DOI:10.1093/eurjcn/zvab135.; Fleeman B.E. Aleong R.G. Optimal strategies to reduce inappropriate implantable cardioverter-defibrillator shocks. Innov. Card. Rhythm. Manag. 2019;10(4):3623–3632. DOI:10.19102/icrm.2019.100403.; Stiles M.K., Fauchier L., Morillo C.A., Wilkoff B.L. 2019 HRS/EHRA/ APHRS/LAHRS focused update to 2015 expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Heart Rhythm. 2020;17(1):220–228. DOI:10.1016/j.hrthm.2019.02.03.; Joung B. Lexcen D., Ching C., Silver M., Piccini J., Sterns L. et al. Additional antitachycardia pacing programming strategies further reduce unnecessary implantable cardioverter-defibrillator shocks. Heart Rhythm. 2020;17(1):98–105. DOI:10.1016/j.hrthm.2019.07.027.; Tan V., Wilton S., Kuriachan V., Sumner G., Exner D. Impact of programming strategies aimed at reducing nonessential implantable cardioverter defibrillator therapies on mortality: a systematic review and meta-analysis. Circ. Arrhythm. Electrophysiol. 2014; 7(1):164–70. DOI:10.1161/CIRCEP.113.001217.; Iannaccone M., Nombela-Franco L., Gallone G., Annone U., Di Marco A., Giannini F. et al. Impact of successful chronic coronary total occlusion recanalization on recurrence of ventricular arrhythmias in implantable cardioverter-defibrillator recipients for ischemic cardiomyopathy (VACTO PCI Study). Cardiovasc. Revasc. Med. 2022;43:104–111. DOI:10.1016/j.carrev.2022.03.029.; Barsheshet A., Goldenberg I., Moss A., Huang D., Zareba W., McNITT S. Effect of elapsed time from coronary revascularization to implantation of a Cardioverter defibrillator on long-term survival in the MADIT-II trial. J. Cardiovasc. Electrophysiol. 2011;22(11):1237–1242. DOI:10.1111/j.1540-8167.2011.02096.; Ursaru A.M., Petris A., Costache I. Comparable efficacy in ischemic and non-ischemic ICD recipients for the primary prevention of sudden cardiac death. Biomedicines. 2021;9(11):1595. DOI:10.3390/biomedicines9111595.; Илов Н.Н., Пальникова О.В., Стомпель Д.Р., Нечепуренко А.А. Клинические предикторы возникновения желудочковых тахиаритмий у больных со сниженной систолической функцией левого желудочка. Результаты одноцентрового проспективного исследования. Кардиология. 2021;61(5):32–40. DOI:10.18087/cardio.2021.5.n1480.; Лебедева В.К., Любимцева Т.А., Лебедев Д.С. Анализ электротерапии кардиовертерами-дефибрилляторами, имплантируемыми с целью первичной профилактики внезапной сердечной смерти. Российский кардиологический журнал. 2019;(7):26–32. DOI:10.15829/1560-4071-2019-7-26-32.; Чугунов И.А., Мареев Ю.В., Фудим М., Миронова Н.А., Мареев В.Ю., Давтян К.В. Модуляция сердечной сократимости в лечении пациентов с сердечной недостаточностью со сниженной фракцией выброса левого желудочка. Кардиология. 2022: 62(11):71–78. DOI:10.18087/cardio.2022.11.n2014.; Oosterwerff E., Adiyaman A., Elvan A., Ghani A., Hoek L., Breeman K. et al. Significantly less inappropriate shocks in ischemic patients compared to non-ischemic patients: The S-ICD experience of a high volume single-center. Pacing Clin. Electrophysiol. 2021;44(11):1918–1924. DOI:10.1111/pace.14364.; Moradi M., Shahabi J., Vakhshoori M., Shafie D. Associated factors with the occurrence of inappropriate shocks among admitted patients with ischemic cardiomyopathy. ARYA Atheroscler. 2022;18(10):1–7. DOI:10.48305/arya.2022.11742.2372.; Defaye P., Boveda S., Klug D., Beganton F., Piot O., Narayanan K. et al. Dualvs. single-chamber defibrillators for primary prevention of sudden cardiac death: long-term follow-up of the Defibrillateur Automatique Implantable-Prevention Primaire registry. Europace. 2017;19(9):1478– 1484. DOI:10.1093/europace/euw230.; Peterson P.N., Greenlee R.T., Go A.S. Comparison of inappropriate shocks and other health outcomes between singleand dual-chamber implantable cardioverter-defibrillators for primary prevention of sudden cardiac death: results from the Cardiovascular Research Network Longitudinal Study of Implantable Cardioverter-Defibrillators. J. Am. Heart Assoc. 2017;6(11):e006937. DOI:10.1161/JAHA.117.006937.; Burger A.L., Schmidinger H., Ristl R., Pezawas T. Appropriate and inappropriate therapy in patients with singleor multi-chamber implantable cardioverter-defibrillators. Hellenic J. Cardiol. 2020;61(6):421–427. DOI:10.1016/j.hjc.2020.03.001.; https://www.sibjcem.ru/jour/article/view/2059

Διαθεσιμότητα: https://www.sibjcem.ru/jour/article/view/2059
https://doi.org/10.29001/2073-8552-2023-38-4-106-115

View record from BASE

3

Academic Journal

Safety and Tolerability of Implanted Subcutaneous Cardioverter-Defibrillator Systems ; Безопасность и переносимость имплантированных подкожных систем кардиовертеров-дефибрилляторов

Συγγραφείς: A. V. Vereshchagina, T. M. Uskach, O. V. Sapelnikov, V. A. Amanatova, I. R. Grishin, A. A. Kulikov, V. S. Kostin, R. S. Akchurin, А. В. Верещагина, Т. М. Ускач, О. В. Сапельников, В. A. Аманатова, И. Р. Гришин, А. А. Куликов, В. С. Костин, Р. С. Акчурин

Συνεισφορές: The study was performed with the support of the National Medical Research Centre of Cardiology named after academician E.I. Chazov., Исследование проведено при поддержке Национального медицинского исследовательского центра кардиологии.

Πηγή: Rational Pharmacotherapy in Cardiology; Vol 18, No 4 (2022); 427-432 ; Рациональная Фармакотерапия в Кардиологии; Vol 18, No 4 (2022); 427-432 ; 2225-3653 ; 1819-6446

Θεματικοί όροι: подкожный имплантируемый кардиовертер-дефибриллятор, chronic heart failure with low ejection fraction, subcutaneous implantable cardioverter-defibrillator, хроническая сердечная недостаточность с низкой фракцией выброса

Περιγραφή αρχείου: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2793/2342; Moss AJ, Hall WJ, Cannom DS, et. al. Improved Survival with an Implanted Defibrillator in Patients with Coronary Disease at High Risk for Ventricular Arrhythmia. New Engl J Med. 1996;335(26):1933-40. DOI:10.1056/nejm199612263352601.; Moss AJ, Zareba W, Hall WJ, et. al. Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection Fraction. New Engl J Med. 2002;346(12):877-83. DOI:10.1056/nejmoa013474.; Kong MH, Fonarow G C, Peterson ED, et. al. Systematic review of the incidence of sudden cardiac death in the United States. J Am Coll Cardiol. 2011;57(7):794-801. DOI:10.1016/j.jacc.2010.09.064.; Kaya E, Rassaf T, Wakili R. Subcutaneous ICD: Current standards and future perspective. Int J Cardiol Heart Vasc. 2019;24:100409. DOI:10.1016/j.ijcha.2019.100409.; Honarbakhsh S, Providencia R, Srinivasan N, et al. A propensity matched case-control study comparing efficacy, safety and costs of the subcutaneous vs. transvenous implantable cardioverter defibrillator. Int J Cardiol. 2017;228:280-5. DOI:10.1016/j.ijcard.2016.11.017.; Olde Nordkamp LO, Knops R, Bardy G, et. al. Rationale and design of the PRAETORIAN trial: a Prospective, Randomized comparison of subcutaneous and transvenous implantable cardioverterdefibrillator therapy. American heart journal. 2012;163(5):753-760. Doi:10.1016/j.ahj.2012.02.012.; Gold S MR, Aasbo JD, El-Chami MF, et al. Subcutaneous implantable cardioverter-defibrillator PostApproval Study: clinical characteristics and perioperative results. Heart Rhythm. 2017;10(14):1456-63. DOI:10.1016/j.hrthm.2017.05.016.; Kamp Nicholas J, Al-Khatib Sana M. The subcutaneous implantable cardioverter-defibrillator in review. Am Heart J. 2019;217:131-9. DOI:10.1016/j.ahj.2019.08.010.; Weiss R, Knight BP, Gold MR, et. al. Safety and efficacy of a totally subcutaneous implantablecardioverter defibrillator. Circulation. 2013;128(9):944-53. DOI:10.1161/CIRCULATIONAHA.113.003042.; Boersma L, Barr C, Knops R, et. al. Implant and Midterm Outcomes of the Subcutaneous Implantable Cardioverter-Defibrillator Registry: The EFFORTLESS Study. J Am Coll Cardiol. 2017;70(7):842-4. DOI:10.1016/j.jacc.2017.06.040.; Knops RE, Olde Nordkamp LRA, Delnoy PPHM, et. al. Subcutaneous or Transvenous Defibrillator Therapy Collaborators. New Engl J Med. 2020;383:526-36. DOI:10.1056/NEJMoa1915932.; Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Journal of the American College of Cardiology. 2018;72(2):91-220. DOI:10.1016/j.hrthm.2017.10.035.; Priori SG, Blomstrom-LundqvistC, Mazzanti A, et. al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2015;36(41):2793-867. DOI:10.1093/eurheartj/ehv316.; Лебедев Д.С., Михайлов Е.Н., Неминущий Н.М., и др. Желудочковые нарушения ритма. Желудочковые тахикардии и внезапная сердечная смерть. Клинические рекомендации 2020. Российский Кардиологический Журнал. 2021;26(7):4600. DOI:10.15829/1560-4071-2021-4600.; Larbig R, Bettin M, Motloch LJ, et al. Management of inappropriate shocks/T-wave-oversensing in S-ICD®-patients. Herzschr Elektrophys. 2018;29(1):122-6. DOI:10.1007/s00399-018-0555-1.; Rhythm Management Product Performance Report Q3 Edition 2021 [cited 2022 Jan 10]. Available from: https://www.bostonscientific.com/content/dam/bostonscientific/quality/ppr/2021/q3/Q3%202021%20CRM%20Product%20Performance%20Report%20Rev%20B.pdf.; Gold MR, Lambiase PD, El-Chami MF, et. al. Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial. Circulation. 2021;143(1):7-17. DOI:10.1161/CIRCULATIONAHA.120.048728.; Moss AJ, Schuger C, Beck CA, et al., for the MADIT-RIT Trial, Investigators Reduction in Inappropriate Therapy and Mortality through ICD Programming. New England Journal of Medicine. 2012;367(24):2275-83. DOI:10.1056/NEJMoa1211107.; Lambiase P.D., Barr C., Theuns D.A., et. al. Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry. Eur Heart J. 2014;35(25):1657-65. DOI:10.1093/eurheartj/ehu112.; Burke MC, Gold MR, Knight BP, et. al. Safety and efficacy of the totally subcutaneous implantable defibrillator: 2-year results from a pooled analysis of the IDE Study and EFFORTLESS Registry. Journal of the American College of Cardiology. 2015;65(16):1605-15. DOI:10.1016/j.jacc.2015.02.047.; Boersma L, Burke MC, Neuzil P, et. al. Infection and mortality after implantation of a subcutaneous ICD after transvenous ICD extraction. Heart Rhythm. 2016;13(1):157-64. DOI:10.1016/j.hrthm.2015.08.039.; Knops RE, Brouwer TF, Barr CS et al. The learning curve associated with the introduction of the subcutaneous implantable defibrillator. Europace. 2016;18(7):1010-5. DOI:10.1093/europace/euv299.; https://www.rpcardio.com/jour/article/view/2793

Διαθεσιμότητα: https://www.rpcardio.com/jour/article/view/2793
https://doi.org/10.20996/1819-6446-2022-08-05

View record from BASE

4

Academic Journal

Remote monitoring of chronic noncommunicable diseases: potential in the COVID-19 pandemic ; Удаленный мониторинг хронических неинфекционных заболеваний: потенциал в условиях пандемии COVID-19

Συγγραφείς: O. Kobyakova S., I. Deev A., D. Tyufilin S., G. Alexandrov O., E. Kulikov S., О. Кобякова С., И. Деев А., Д. Тюфилин С., Г. Александров О., Е. Куликов С.

Πηγή: Bulletin of Siberian Medicine; Том 21, № 1 (2022); 109-120 ; Бюллетень сибирской медицины; Том 21, № 1 (2022); 109-120 ; 1819-3684 ; 1682-0363 ; 10.20538/1682-0363-2022-21-1

Περιγραφή αρχείου: application/pdf

Relation: https://bulletin.tomsk.ru/jour/article/view/4706/3163; https://bulletin.tomsk.ru/jour/article/view/4706/3186; Forouzanfar M.H., Afshin A., Alexander L.T. et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388(10053):1659–1724. DOI:10.1016/S0140-6736(16)31679-8.; Zhang X., Zaman B. Adoption mechanism of telemedicine in underdeveloped country. Health Informatics J. 2020;26(2):1088–1103. DOI:10.1177/1460458219868353.; Fryer K., Delgado A., Foti T., Reid CN., Marshall J. Implementation of obstetric telehealth during COVID-19 and beyond. Matern. Chil. Health J. 2020;24(9):1104–1110. DOI:10.1007/s10995-020-02967-7.; Петрова Р.Е., Шеяфетдинова Н.А, Соловьев А.А., Глобенко О.А., Портная Е.Б., Рыбаков О.Ю. и др. Современное состояние развития телемедицины в России: правовое и законодательное регулирование. Профилактическая медицина. 2019;22(2):5–9. DOI:10.17116/profmed2019220215.; Martínez-García M., Bal-Alvarado M., Santos Guerra F. et al. Telemedicina con telemonitorización en el seguimiento de pacientes con COVID-19. Rev. Clínica Esp. 2020:S0014256520301557. DOI:10.1016/j.rce.2020.05.013.; Smith A.C., Thomas E., Snoswell C.L. et al. Telehealth for global emergencies: implications for coronavirus disease 2019 (COVID-19). J. Telemed. Telecare. 2020;26(5):309–313. DOI:10.1177/1357633X20916567.; Рекомендации ВОЗ для населения. 2020. URL: https://www.who.int/ru/emergencies/diseases/novel-coronavirus-2019/advice-for-public; CDC. Coronavirus disease 2019 (COVID-19). Centers for disease control and prevention. URL: https://www.cdc.gov/coronavirus/2019-ncov/global-covid-19/operational-considerations-contact-tracing.html; Dobrow M. Caring for people with chronic conditions: a health system perspective. Int. J. Integr. Care. 2009;9(1). DOI:10.5334/ijic.298.; Scott R.E., Mars M. Response to Smith et al. Telehealth for global emergencies: implications for coronavirus disease 2019 (COVID-19). J. Telemed. Telecare. 2020;26(6):378–380. DOI:10.1177/1357633X20932416.; O’Hara V.M., Johnston S.V., Browne N.T. The paediatric weight management office visit via telemedicine: pre‐ to post‐ COVID‐19 pandemic. Pediatr. Obes. 2020;15(8). DOI:10.1111/ijpo.12694.; NCDs. Assessing national capacity for the prevention and control of NCDs. WHO. 2020. URL: http://www.who.int/ncds/surveillance/ncd-capacity/en/; Кобякова О.С., Деев И.А., Куликов Е.С., Старовойтова Е.А., Малых Р.Д., Балаганская М.А., Загромова Т.А. Хронические неинфекционные заболевания: эффекты сочетанного влияния факторов риска. Профилактическая медицина. 2019;22(2):45. DOI:10.17116/profmed20192202145.; Cruz-Martínez R.R., Wentzel J., Asbjørnsen R.A. et al. Supporting self-management of cardiovascular diseases through remote monitoring technologies: metaethnography review of frameworks, models, and theories used in research and development. J. Med. Internet. Res. 2020;22(5):e16157. DOI:10.2196/16157.; Varma N., Epstein A.E., Irimpen A., Schweikert R., Love C. Efficacy and safety of automatic remote monitoring for implantable cardioverter-defibrillator follow-up: the lumos-t safely reduces routine office device follow-up (TRUST) trial. Circulation. 2010;122(4):325–332. DOI:10.1161/CIRCULATIONAHA.110.937409.; Mendes-Ferreira P., Maia-Rocha C, Adao R. et al. Targeting pulmonary artery pressures in the treatment of chronic heart failure: insights from the CHAMPION trial. Eur. Heart J. 2012;33(1):339–653. DOI:10.1093/eurheartj/ehs282.; Lim P., Lee A., Chua K. et al. Remote monitoring of patients with cardiac implantable electronic devices: a Southeast Asian, single-centre pilot study. Singapore Med. J. 2016;57(07):372–377. DOI:10.11622/smedj.2016120.; Guedon-Moreau L., Lacroix D., Sadoul N. et al. A randomized study of remote follow-up of implantable cardioverter defibrillators: safety and efficacy report of the ECOST trial. Eur. Heart J. 2013;34(8):605–614. DOI:10.1093/eurheartj/ehs425.; Mabo P., Victor F., Bazin P. et al. A randomized trial of long-term remote monitoring of pacemaker recipients (The COMPAS trial). Eur. Heart J. 2012;33(9):1105–1111. DOI:10.1093/eurheartj/ehr419.; Versteeg H., Timmermans I., Widdershoven J. et al. Effect of remote monitoring on patient-reported outcomes in European heart failure patients with an implantable cardioverter-defibrillator: primary results of the REMOTE-CIED randomized trial. EP Eur. 2019;21(9):1360–1368. DOI:10.1093/europace/euz140.; Crossley G.H., Boyle A., Vitense H., Chang Y., Mead R.H. The CONNECT (clinical evaluation of remote notification to reduce time to clinical decision) trial. J. Am. Coll. Cardiol. 2011;57(10):1181–1189. DOI:10.1016/j.jacc.2010.12.012.; Abraham W.T., Stevenson L.W., Bourge R.C., Lindenfeld J.A., Bauman J.G., Adamson P.B. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. Lancet. 2016;387(10017):453–461. DOI:10.1016/S0140-6736(15)00723-0.; Abraham W.T., Adamson P.B., Bourge R.C. et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377(9766):658–666. DOI:10.1016/S0140-6736(11)60101-3.; Adamson P.B., Abraham W.T., Aaron M. et al. CHAMPION trial rationale and design: the long-term safety and clinical efficacy of a wireless pulmonary artery pressure monitoring system. J. Card. Fail. 2011;17(1):3–10. DOI:10.1016/j.cardfail.2010.08.002.; Heywood J.T., Jermyn R., Shavelle D. et al. Impact of practice-based management of pulmonary artery pressures in 2000 patients implanted with the CardioMEMS sensor. Circulation. 2017;135(16):1509–1517. DOI:10.1161/CIRCULATIONAHA.116.026184.; Yousefian O., Wolfson A., Shavelle D. Remote haemodynamic monitoring in patients excluded from champion trial. J. Investig. Med. 2018;66(1). DOI:10.1136/jim-2017-000663.13.; McKinstry B., Hanley J., Wild S. et al. Telemonitoring based service redesign for the management of uncontrolled hypertension: multicentre randomised controlled trial. BMJ. 2013;346(may24 4):f3030-f3030. DOI:10.1136/bmj.f3030.; Evans J., Papadopoulos A., Silvers C.T. et al. Remote health monitoring for older adults and those with heart failure: adherence and system usability. Telemed. E-health. 2016;22(6):480-488. DOI:10.1089/tmj.2015.0140.; Triantafyllidis A., Velardo C., Chantler T. et al. A personalised mobile-based home monitoring system for heart failure: the SUPPORT-HF study. Int. J. Med. Inf. 2015;84(10):743–753. DOI:10.1016/j.ijmedinf.2015.05.003.; Margolis K.L., Asche S.E., Bergdall A.R. et al. Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial. JAMA. 2013;310(1):46. DOI:10.1001/jama.2013.6549.; Piotrowicz E., Pencina M.J., Opolski G. et al. Effects of a 9-week hybrid comprehensive telerehabilitation program on long-term outcomes in patients with heart failure: the telerehabilitation in heart failure patients (TELEREH-HF) randomized clinical trial. JAMA Cardiol. 2020;5(3):300. DOI:10.1001/jamacardio.2019.5006.; Piotrowicz E., Baranowski R., Bilinska M. et al. A new model of home-based telemonitored cardiac rehabilitation in patients with heart failure: effectiveness, quality of life, and adherence. Eur. J. Heart Fail. 2010;12(2):164–171. DOI:10.1093/eurjhf/hfp181.; Olivari Z., Giacomelli S., Gubian L. et al. The effectiveness of remote monitoring of elderly patients after hospitalisation for heart failure: the renewing health European project. Int. J. Cardiol. 2018;257:137–142. DOI:10.1016/j.ijcard.2017.10.099.; Halcox J.P. J., Wareham K., Cardew A. et al. Assessment of remote heart rhythm sampling using the alivecor heart monitor to screen for atrial fibrillation: the REHEARSE-AF study. Circulation. 2017;136(19):1784–1794. DOI:10.1161/CIRCULATIONAHA.117.030583.; Reed M.J., Grubb N.R., Lang C.C. et al. Multi-centre randomised controlled trial of a smart phone-based event recorder alongside standard care versus standard care for patients presenting to the emergency department with palpitations and pre-syncope – the IPED (investigation of palpitations in the ED) study: study protocol for a randomised controlled trial. Trials. 2018;19(1):711. DOI:10.1186/s13063-018-3098-1.; Griksaitis M.J., Rosengarten J.A., Gnanapragasam J.P., Haw M.P., Morgan J.M. Implantable cardioverter defibrillator therapy in paediatric practice: a single-centre UK experience with focus on subcutaneous defibrillation. EP Eur. 2013;15(4):523–530. DOI:10.1093/europace/eus388.; Leyva F., Fernandez Lozano I., Morgan J. Cardioverter-defibrillators: a cost or an investment? Europace. 2011;13(2):ii25-ii31. DOI:10.1093/europace/eur085.; Morgan J.M., Kitt S., Gill J. et al. Remote management of heart failure using implantable electronic devices. Eur. Heart J. 2017;38(30):2352–2360. DOI:10.1093/eurheartj/ehx227.; Boriani G., Cimaglia P., Biffi M. et al. Cost-effectiveness of implantable cardioverter-defibrillator in today’s world. Indian. Heart J. 2014;66:S101–S104. DOI:10.1016/j.ihj.2013.12.034.; Vanezis A.P., Arnold J.R., Rodrigo G. et al. Daily remote ischaemic conditioning following acute myocardial infarction: a randomised controlled trial. Heart. 2018;104(23):1955–1962. DOI:10.1136/heartjnl-2018-313091.; Ломидзе Н.Н., Васковский В.А., Яшков М.В., Артюхина Е.А., Ревишвили А.Ш. Возможности и перспективы удаленного мониторинга пациентов с имплантированными устройствами. Комплексные проблемы сердечно-сосудистых заболеваний. 2019;8(2):98–106. DOI:10.17802/2306-1278-2019-8-2-98-106.; Timmermans I. Remote patient monitoring of implantable cardioverter defibrillators: patient satisfaction and preferences for FOLLOW-UP. Psychosom. Med. 2018;80(3):A1. DOI:10.1097/PSY.0000000000000578.; ВОЗ. Программа по борьбе с хроническими респираторными заболеваниями. URL: https://www.who.int/respiratory/about_us/ru/; Lilholt P.H., Witt Udsen F., Ehlers L., Hejlesen O.K. Telehealthcare for patients suffering from chronic obstructive pulmonary disease: effects on health-related quality of life: results from the Danish ‘TeleCare North’ cluster-randomised trial. BMJ Open. 2017;7(5):e014587. DOI:10.1136/bmjopen-2016-014587.; Walker P.P., Pompilio P.P., Zanaboni P. et al. Telemonitoring in chronic obstructive pulmonary disease (CHROMED). A randomized clinical trial. Am. J. Respir. Crit. Care Med. 2018;198(5):620–628. DOI:10.1164/rccm.201712-2404OC.; Vianello A., Fusello M., Gubian L. et al. Home telemonitoring for patients with acute exacerbation of chronic obstructive pulmonary disease: a randomized controlled trial. BMC Pulm. Med. 2016;16(1):157. DOI:10.1186/s12890-016-0321-2.; Pinnock H., Hanley J., McCloughan L. et al. Effectiveness of telemonitoring integrated into existing clinical services on hospital admission for exacerbation of chronic obstructive pulmonary disease: researcher blind, multicentre, randomised controlled trial. BMJ. 2013;347(173):f6070–f6070. DOI:10.1136/bmj.f6070.; Rixon L., Hirani S.P., Cartwright M. et al. A RCT of telehealth for COPD patient’s quality of life: the whole system demonstrator evaluation: COPD patient’s quality of life. Clin. Respir J. 2017;11(4):459–469. DOI:10.1111/crj.12359.; Farmer A., Williams V., Velardo C. et al. Self-management support using a digital health system compared with usual care for chronic obstructive pulmonary disease: randomized controlled trial. J. Med. Internet. Res. 2017;19(5):e144. DOI:10.2196/jmir.7116.; Sirichana V.I., Patel M.H., Wang X. et al. Choices of spirometry measures for remote patient monitoring in COPD. In: B43. COPD: screening and diagnostic tools. American Thoracic Society International Conference Abstracts. American Thoracic Society; 2014:A2971–A2971. DOI:10.1164/ajrccm-conference.2014.189.1_MeetingAbstracts.A2971.; Makhinova T., Barner J.C., Richards K.M., Rascati K.L. Asthma controller medication adherence, risk of exacerbation, and use of rescue agents among texas medicaid patients with persistent asthma. J. Manag. Care Spec. Pharm. 2015;21(12):1124-1132. DOI:10.18553/jmcp.2015.21.12.1124.; Barrett M.A., Humblet O., Marcus J.E. et al. Effect of a mobile health, sensor-driven asthma management platform on asthma control. Ann. Allergy Asthma Immunol. 2017;119(5):415–421. e1. DOI:10.1016/j.anai.2017.08.002.; Merchant R.K., Inamdar R., Quade R.C. Effectiveness of population health management using the propeller health asthma platform: a randomized clinical trial. J. Allergy Clin. Immunol. Pract. 2016;4(3):455–463. DOI:10.1016/j.jaip.2015.11.022.; Kew K.M., Cates C.J. Remote versus face-to-face checkups for asthma. Cochrane Database Syst. Rev. 2016. DOI:10.1002/14651858.CD011715.pub2.; De Jongste J.C., Carraro S., Hop W.C., the CHARISM Study Group, Baraldi E. Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. Am. J. Respir. Crit. Care Med. 2009;179(2):93–97. DOI:10.1164/rccm.200807-1010OC.; IDF Diabetes Atlas 9th edition 2019. URL: https://www.diabetesatlas.org/en/; Lee J.Y., Wong C.P., Tan C.S.S., Nasir N.H., Lee S.W.H. Telemonitoring in fasting individuals with type 2 diabetes mellitus during ramadan: prospective, randomised controlled study. Sci. Rep. 2017;7(1):10119. DOI:10.1038/s41598-017-10564-y.; Michaud T.L., Siahpush M., Schwab R.J. et al. Remote patient monitoring and clinical outcomes for postdischarge patients with type 2 diabetes. Popul. Health Manag. 2018;21(5):387 DOI:10.1089/pop.2017.0175.; Steventon A., Bardsley M., Doll H., Tuckey E., Newman S.P. Effect of telehealth on glycaemic control: analysis of patients with type 2 diabetes in the Whole Systems Demonstrator cluster randomised trial. BMC Health Serv. Res. 2014;14(1):334. DOI:10.1186/1472-6963-14-334.; Wild S.H., Hanley J., Lewis S.C. et al. Supported telemonitoring and glycemic control in people with type 2 diabetes: the telescot diabetes pragmatic multicenter randomized controlled trial. PLOS Med. 2016;13(7):e1002098. DOI:10.1371/journal.pmed.1002098.; Jeong J.Y., Jeon J.-H., Bae K.-H. et al. Smart care based on telemonitoring and telemedicine for type 2 diabetes care: multi-center randomized controlled trial. Telemed. E-Health. 2018;24(8):604–613. DOI:10.1089/tmj.2017.0203.; Dario C., Toffanin R., Calcaterra F. et al. Telemonitoring of type 2 diabetes mellitus in Italy. Telemed E-Health. 2017;23(2):143–152. DOI:10.1089/tmj.2015.0224.; Лебедев Г.С., Шадеркин И.А., Фомина И.В. и др. Основные направления развития интернет-технологий в здравоохранении (систематический обзор). Социальные аспекты здоровья населения. 2017;57(5). URL: https://cyberleninka.ru/article/n/osnovnye-napravleniya-razvitiya-internet-tehnologiy-v-zdravoohranenii-sistematicheskiy-obzor; Pounds G., Murphy J.J. Remote monitoring of ILRs, when is more too much? EP Eur. 2017;19(1):i57. DOI:10.1093/europace/eux283.133.; Heidbuchel H., Hindricks G., Broadhurst P. et al. EuroEco (European health economic trial on home monitoring in ICD patients): a provider perspective in five European countries on costs and net financial impact of follow-up with or without remote monitoring. Eur. Heart J. 2015;36(3):158–169. DOI:10.1093/eurheartj/ehu339.; Massaroni C., Nicolò A., Schena E., Sacchetti M. Remote respiratory monitoring in the time of COVID-19. Front Physiol. 2020;11:635. DOI:10.3389/fphys.2020.00635.; Guzik T.J., Mohiddin S.A., Dimarco A. et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020;116(10):1666–1687. DOI:10.1093/cvr/cvaa106.; Barney A., Buckelew S., Mesheriakova V., Raymond-Flesch M. The COVID-19 pandemic and rapid implementation of adolescent and young adult telemedicine: challenges and opportunities for innovation. J. Adolesc. Health. 2020;67(2):164–171. DOI:10.1016/j.jadohealth.2020.05.006.; Prasad A., Brewster R., Newman J.G., Rajasekaran K. Optimizing your telemedicine visit during the COVID ‐19 pandemic: practice guidelines for patients with head and neck cancer. Head Neck. 2020;42(6):1317–1321. DOI:10.1002/hed.26197.; Capucci A., De Simone A., Luzi M. et al. Economic impact of remote monitoring after implantable defibrillators implantation in heart failure patients: an analysis from the EFFECT study. EP Eur. 2017;19(9):1493–1499. DOI:10.1093/europace/eux017.; Klersy C., De Silvestri A., Gabutti G. et al. Economic impact of remote patient monitoring: an integrated economic model derived from a meta-analysis of randomized controlled trials in heart failure. Eur. J. Heart Fail. 2011;13(4):450–459. DOI:10.1093/eurjhf/hfq232.; Hummel J.P., Leipold R.J., Amorosi S.L. et al. Outcomes and costs of remote patient monitoring among patients with implanted cardiac defibrillators: an economic model based on the PREDICT RM database. J. Cardiovasc. Electrophysiol. 2019;30(7):1066–1077. DOI:10.1111/jce.13934.; Sheppard J.P., Tucker K.L., Davison W.J. et al. Self-monitoring of blood pressure in patients with hypertension-related multi-morbidity: systematic review and individual patient data meta-analysis. Am. J. Hypertens. 2019:hpz182. DOI:10.1093/ajh/hpz182.; Sterling R., LeRouge C. On-demand telemedicine as a disruptive health technology: qualitative study exploring emerging business models and strategies among early adopter organizations in the United States. J. Med. Internet Res. 2019;21(11):e14304. DOI:10.2196/14304.; https://bulletin.tomsk.ru/jour/article/view/4706

Διαθεσιμότητα: https://bulletin.tomsk.ru/jour/article/view/4706
https://doi.org/10.20538/1682-0363-2022-1-109-120

View record from BASE

5

Academic Journal

Diagnosis and treatment of syncope

Συγγραφείς: Tseluyko, V. Y., Radchenko, O. V.

Πηγή: Medicine of Ukraine; № 7(223) (2018); 10-26
Лекарства Украины; № 7(223) (2018); 10-26
Ліки України; № 7(223) (2018); 10-26

Θεματικοί όροι: 616.12 009.86 079.4, непритомність, короткочасна втрата свідомості, вазовагальна непритомність, рефлекторний обморок, ортостатична гіпотензія, серцева непритомність, раптова серцева смерть, електрофізіологічне дослідження, моніторинг ЕКГ, тілт-тест, масаж каротидного синуса, кардіостимуляція, імплантований кардіовертер, обморок, кратковременная потеря сознания, вазовагальный обморок, рефлекторный обморок, ортостатическая гипотензия, сердечный обморок, внезапная сердечная смерть, электрофизиологическое исследование, мониторинг ЭКГ, тилт-тест, массаж каротидного синуса, кардиостимуляция, имплантируемый кардиовертер, syncope, transient loss of consciousness, vasogagal syncope, reflex syncope, orthostatic hypotension, cardiac syncope, sudden cardiac death, electrophysiological examination, ECG monitoring, tilt test, carotid sinus massage, pacing, implantable cardioverter defibrillator, 3. Good health

Περιγραφή αρχείου: application/pdf

Σύνδεσμος πρόσβασης: http://lu-journal.com.ua/article/download/199772/199963
http://lu-journal.com.ua/article/view/199772

View record at OpenAIRE

6

Academic Journal

Ventricular extrasystole: clinical significance, prognosis and treatment ; Extrasistolia ventriculară: semnificație clinică, prognostic și tratament ; Желудочковая экстрасистолия: клиническое значение, прогноз и лечение

Συγγραφείς: Grosu, Aurel

Πηγή: Bulletin of the Academy of Sciences of Moldova. Medical Sciences; Vol. 65 No. 1 (2020): Medical Sciences; 59-67 ; Buletinul Academiei de Științe a Moldovei. Științe medicale; Vol. 65 Nr. 1 (2020): Ştiinţe medicale; 59-67 ; Вестник Академии Наук Молдовы. Медицина; Том 65 № 1 (2020): Медицина; 59-67 ; 1857-0011

Θεματικοί όροι: ventricular extrasystole, radiofrequency transcateter ablation, implantable cardioverter, желудочковая экстрасистолия, радиочастотная транскатетерная абляция, имплантируемый кардиовертер, extrasistolie ventriculară, ablație transcateter cu radiofrecvență, cardioverter implantabil

Περιγραφή αρχείου: application/pdf

Relation: https://bulmed.md/bulmed/article/view/3167/3167; https://bulmed.md/bulmed/article/view/3167

Διαθεσιμότητα: https://bulmed.md/bulmed/article/view/3167

View record from BASE

7

Academic Journal

Extrasistolia ventriculară: semnificație clinică, prognostic și tratament

Συγγραφείς: Grosu, A.A.

Πηγή: Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale 65 (1) 59-67

Θεματικοί όροι: extrasistolie ventriculară, ablație transcateter cu radiofrecvență, cardioverter implantabil, желудочковая экстрасистолия, радиочастотная транскатетерная абляция, имплантируемый кардиовертер, ventricular extrasystole, radiofrequency transcateter ablation, implantable cardioverter

Περιγραφή αρχείου: application/pdf

Relation: https://ibn.idsi.md/vizualizare_articol/114993; urn:issn:18570011

Διαθεσιμότητα: https://ibn.idsi.md/vizualizare_articol/114993

View record from BASE

8

Academic Journal

Удаление электродов имплантированных систем. Состояние проблемы

Συγγραφείς: О. Сапельников, А. Куликов, Д. Черкашин, И. Гришин, О. Николаева, Д. Ардус, А. Ширяев, Р. Акчурин

Πηγή: Патология кровообращения и кардиохирургия, Vol 23, Iss 4 (2019)

Θεματικοί όροι: имплантируемый кардиовертер-дефибриллятор, имплантируемое устройство, электрокардиостимулятор, экстракция электродов, Surgery, RD1-811

Περιγραφή αρχείου: electronic resource

Relation: https://journalmeshalkin.ru/index.php/heartjournal/article/view/676; https://doaj.org/toc/1681-3472; https://doaj.org/toc/2500-3119

Σύνδεσμος πρόσβασης: https://doaj.org/article/79b124857f244a7cb3aa198fd2f96c0e

View record in DOAJ Full Text Finder

9

Academic Journal

Atrial Fibrillation and Ventricular Arrhythmias in ST Segment Elevation Myocardial Infarction: Possibilities of Pharmacotherapy and Non-Pharmacological Treatment ; Фибрилляция предсердий и желудочковые аритмии при инфаркте миокарда с подъемом сегмента ST: возможности фармакотерапии и немедикаментозного лечения

Συγγραφείς: Yu. Bunin A., S. Miklisanskaya A., V. Chigineva V., E. Zolozova A., Ю. Бунин А., С. Миклишанская В., В. Чигинева В., Е. Золозова А.

Πηγή: Rational Pharmacotherapy in Cardiology; Vol 14, No 4 (2018); 605-611 ; Рациональная Фармакотерапия в Кардиологии; Vol 14, No 4 (2018); 605-611 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2018-14-4

Θεματικοί όροι: atrial fibrillation, ventricular arrhythmias, ST-segment elevation myocardial infarction, beta-blockers, amiodarone, pharmacological cardioversion, electrical cardioversion, implantable cardioverter-defibrillator, фибрилляция предсердий, желудочковые аритмии, инфаркт миокарда с подъемом сегмента ST, бета-адреноблокаторы, амиодарон, фармакологическая кардиоверсия, электроимпульсная терапия, имплантируемый кардиовертер-дефибриллятор

Περιγραφή αρχείου: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/1732/1698; 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting withST-segment elevation. Eur Heart J. 2018;39:119-77. doi:10.1093/eurheartj/ehx393.; Schmitt J., Duray G., Gersh B.J., Hohnloser S.H. Atrial fibrillation in acute myocardial infarction. Eur Heart J. 2009;30:1038-45. doi:10.1093/eurheartj/ehn579.; Jabre P., Jouven X., Adnet F. et al. Atrial fibrillation and death аfter myocardial infarction: a community study. Circulation. 2011;123:2094-100. doi:10.1161/CIRCULATIONAHA.110.990192.; Jabre P., Roder V.L., Murad M.H. et al. Mortality associated with atrial fibrillation in patients with myocardial infarction. Circulation. 2011;123:1587-93. doi.org/10.1161/CIRCULATIONAHA. 110.986661.; Crenshow B.S., Ward S.R., Granger C.B. et al. Atrial fibrillation in the setting of acute myocardial infarction. J Am Coll Cardiol. 1997;30:406-13.; Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA and EAPCI task force. Europace. 2014;16:1655-673. doi:10.1093/europace/euu208.; 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. J. Am. Coll. Cardiol. 2014;64(21):e1-e76. doi:10.1016/j.jacc.2014.03.022.; 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2018;39(3):213-60. doi.org/10.1093/eurheartj/ehx419.; Risius T., Mortensen K., Schwermer T.F. et al.Comparison of anterio-lateral versus anterio-posterior electrode position for biphasic external cardioversion of atrial flutter. Am J Cardiol. 2009;104:154750. doi:10.1016/j.amjcard.2009.07.027.; Manegold J.C., Israel C.W., Ehrlich J.R. et al. External cardioversion of atrial fibrillation in patients with implanted pacemaker or cardioverter-defibrillator. Eur Heart J. 2007;28:1731-8. doi:10.1093/eurheartj/ehm211.; Priori S.G., Blomstrom-Lundgvist C., Mazzanti A. et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur. Heart J. 2015;36:2793-867. doi:10.1093/europace/euv319.; Piccini J.P., Schulte P.J., Pieper K.S. et al. Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction. Crit Care Med. 2011;39:78-83. doi:10.1097/CCM.0b013e3181fd6ad7.; He X.Z., Zhou S.H., Wan X.H. et al. The effect early and intensive statin therapy on ventricular premature beat or nonsustained ventricular tachycardia in patients with acute coronary syndrome. Clin Cardiol. 2011;34:59-63. doi:10.1002/clc.20818.; 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2015;36(41):2793-867. doi:10.1093/eurheartj/ ehv316.; 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. Circulation. 2013;127:e362-e425. doi:10.1161/CIR.0b013e3182742cf6.; Cardiac Arrhythmia Suppression Trial (CAST) investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321(6):406-12. doi:10.1056/NEJM198908103210629.; The cardiac arrhythmia suppression trial II investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med. 1992;327(4):227-33. doi:10.1056/NEJM199207233270403.; Teo K.K., Yusuf S., Furberg C.D. Effects prophylactic antiarrhythmic drug therapy in acute myocardial infarction. JAMA. 1993;270(13):1589-95.; Antman E.M. ST-elevation myocardial infarction: management. In Braunwald E., Zipes L., Libby P., Bonow R. (eds). Heart disease. Philadelphia: W.B. Saunders company; 2005. P.1167-1226.; Бунин Ю.А. Возможности антиаритмической терапии в первичной профилактике смерти у больных с желудочковыми аритмиями. Рациональная Фармакотерапия в Кардиологии. 2010;6(6):870-5. doi:10.20996/1819-6446-2010-6-6-870-875.; Bardy G.H., Lee K.L., Mark D.B. et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-37. doi:10.1056/NEJMoa043399.; Boutitie F., Boissel J.P., Connoly S.J. et al. Amiodarone interaction with beta-blokers: analysis of the merged EMIAT and CAMIAT detabases. Circulation. 1999;99:2268-75. doi:10.1161/01.CIR. 99.17.2268.; 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. ACC (2017). J Am Coll Cardiol. 2017 Oct 25. pii: S07351097(17)41306-4. doi:10.1016/j.jacc.2017.10.054.; https://www.rpcardio.com/jour/article/view/1732

Διαθεσιμότητα: https://www.rpcardio.com/jour/article/view/1732
https://doi.org/10.20996/1819-6446-2018-14-4-605-611

View record from BASE

10

Academic Journal